Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data

Published on 17 May 2023 on Bloomberg via Yahoo Finance

(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.

Start tracking your investments with Statfolio

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarte...

Insider Monkey via Yahoo Finance 18 May 2023

(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this s...

Bloomberg via Yahoo Finance 17 May 2023

Investors are scrambling to assess the fallout of a U.S. regulatory challenge against Amgen Inc's...

Reuters via Yahoo News 17 May 2023

Stock-market investors are soon facing a reconstitution of U.S. Russell indexes, an annual proces...

Market Watch 16 May 2023

The Federal Trade Commission is suing to block biopharma giant Amgen Inc.’s proposed acquisition ...

Market Watch 16 May 2023

The U.S. government’s aggressive stance on antitrust is chilling merger activity among the countr...

The Columbian 15 May 2023

Momentum investing revolves around the idea of following a stock's recent trend in either directi...

Zacks via Yahoo Finance 12 May 2023

Biggest movers include Prometheus, Arcellx, and Madrigal, all more than quadrupling in price in t...

Investopedia 11 May 2023

(Bloomberg) -- The US government’s aggressive stance on antitrust is chilling merger activity amo...

Bloomberg via Yahoo News 10 May 2023

Key Insights Institutions' substantial holdings in Prometheus Biosciences implies that they have ...

Simply Wall St. via Yahoo Finance 29 Apr 2023